

## Pacific Blue™ anti-mouse CD8a Antibody

<b>Catalog# / Size</b>	100728 / 25 µg 100725 / 100 µg
<b>Clone</b>	53-6.7
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	T8, Lyt2, Ly-2
<b>Isotype</b>	Rat IgG2a, κ
<b>Description</b>	CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Mouse thymus or spleen
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with Pacific Blue™ under optimal conditions.
<b>Concentration</b>	0.5 mg/ml
<b>Storage &amp; Handling</b>	The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . The suggested use of this reagent is ≤ 0.25 µg per 10 <sup>6</sup> cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application.  * Pacific Blue™ has a maximum emission of 455 nm when it is excited at 405 nm. Prior to using Pacific Blue™ conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.  Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.  <a href="#">View full statement regarding label licenses</a>
<b>Excitation Laser</b>	Violet Laser (405 nm)
<b>Application Notes</b>	Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes <sup>3</sup> . The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a <sup>+</sup> cells. Additional reported applications (for the relevant formats) include: immunoprecipitation <sup>1,3</sup> , <i>in vivo</i> and <i>in vitro</i> cell depletion <sup>2,10,15</sup> , inhibition of CD8 T cell proliferation <sup>3</sup> , blocking of cytotoxicity <sup>3,4</sup> , immunohistochemical staining <sup>5,6</sup> of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX) <sup>29,30</sup> . Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in

vivo studies (Cat No. 100746).

## Application References

(PubMed link indicates  
BioLegend citation)

1. Ledbetter JA, et al. 1979. *Immunol. Rev.* 47:63. (IHC, IP)
2. Hathcock KS. 1991. *Current Protocols in Immunology*. 3.4.1. (Deplete)
3. Takahashi K, et al. 1992. *P. Natl. Acad. Sci. USA* 89:5557. (Block, IP)
4. Ledbetter JA, et al. 1981. *J. Exp. Med.* 153:1503. (Block)
5. Hata H, et al. 2004. *J. Clin. Invest.* 114:582. (IHC)
6. Fan WY, et al. 2001. *Exp. Biol. Med.* 226:1045. (IHC)
7. Shih FF, et al. 2006. *J. Immunol.* 176:3438. (FC)
8. Kamimura D, et al. 2006. *J. Immunol.* 177:306.
9. Bouwer HGA, et al. 2006. *P. Natl. Acad. Sci. USA* 103:5102. (FC, Deplete)
10. Kao C, et al. 2005. *Int. Immunol.* 17:1607. [PubMed](#)
11. Ko SY, et al. 2005. *J. Immunol.* 175:3309. (FC) [PubMed](#)
12. Rasmussen JW, et al. 2006. *Infect. Immun.* 74:6590. [PubMed](#)
13. Lee CH, et al. 2009. *Clin. Cancer Res.* [PubMed](#)
14. Geiben-Lynn R, et al. 2008. *Blood* 112:4585. (Deplete) [PubMed](#)
15. Kingeter LM, et al. 2008. *J. Immunol.* 181:6244. [PubMed](#)
16. Guo Y, et al. 2008. *Blood* 112:480. [PubMed](#)
17. Andrews DM, et al. 2008. *J. Virol.* 82:4931. [PubMed](#)
18. Britschqui MR, et al. 2008. *J. Immunol.* 181:7681. [PubMed](#)
19. Kenna TJ, et al. 2008. *Blood* 111:2091. [PubMed](#)
20. Jordan JM, et al. 2008. *Infect. Immun.* 76:3717. [PubMed](#)
21. Todd DJ, et al. 2009. *J. Exp. Med.* 206:2151. [PubMed](#)
22. Bankoti J, et al. 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
23. Medyouf H, et al. 2010. *Blood* 115:1175. [PubMed](#)
24. Riedl P, et al. 2009. *J. Immunol.* 183:370. [PubMed](#)
25. Apte SH, et al. 2010. *J. Immunol.* 185:998. [PubMed](#)
26. Bankoti J, et al. 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
27. del Rio ML, et al. 2011. *Transpl. Int.* 24:501. (FC) [PubMed](#)
28. Cui L, et al. 2015. *J Control Release.* 206:220. [PubMed](#)
29. Radtke AJ, et al. 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
30. Radtke AJ, et al. 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Chen Y, et al. 2020. *Virol Sin.* . [PubMed](#)
2. Logan K Smith et al. 2018. *Immunity.* 48(2):299-312 . [PubMed](#)
3. Wu J et al. 2017. *Immunity.* 47(6):1114-1128 . [PubMed](#)
4. Tan L, et al. 2022. *Aging Dis.* 13:1562. [PubMed](#)
5. Rosenkranz SC, et al. 2021. *eLife.* 10:00. [PubMed](#)
6. Rezende R, et al. 2015. *Nat Commun.* 6: 8726. [PubMed](#)
7. Schneider C, et al. 2018. *Cell.* 174:271. [PubMed](#)
8. Page N, et al. 2018. *Immunity.* 48:937. [PubMed](#)
9. Gawish R, et al. 2022. *Elife.* 11: . [PubMed](#)
10. Zhu W, et al. 2021. *Onco Targets Ther.* 14:2149. [PubMed](#)
11. Fan L, et al. 2021. *Cancers (Basel).* 13: . [PubMed](#)
12. Hamilton JAG, et al. 2021. *Aging Cell.* 20:e13309. [PubMed](#)
13. Koh CH, et al. 2020. *Cancer Immunol Res.* 8:698. [PubMed](#)
14. Engler J, et al. 2017. *Proc Natl Acad Sci U S A.* 114(2):E181-E190. [PubMed](#)
15. Gupta SS, et al. 2019. *Cell Rep.* 29:1862. [PubMed](#)
16. Wabitsch S, et al. 2021. *Cell Mol Gastroenterol Hepatol.* 12:1166. [PubMed](#)
17. Molofsky A, et al. 2013. *J Exp Med.* 210:535. [PubMed](#)
18. Li Y, et al. 2020. *Cell Rep.* 30:1753. [PubMed](#)
19. Isoda T et al. 2017. *Cell.* 171(1):103-119 . [PubMed](#)
20. Gu M, et al. 2021. *Nat Immunol.* 22:193. [PubMed](#)
21. Galeano Niño JL, et al. 2020. *J Cell Sci.* . [PubMed](#)
22. Saito S, et al. 2020. *Nutrients.* 12: . [PubMed](#)
23. Wabitsch S, et al. 2021. *STAR Protoc.* 2:100517. [PubMed](#)
24. Price J, et al. 2015. *Diabetes.* 64: 3521 - 3531. [PubMed](#)
25. Liang Z, et al. 2021. *J Cell Physiol.* 236:4725. [PubMed](#)
26. Sato Y, et al. 2021. *J Clin Invest.* Online ahead of print. [PubMed](#)
27. Ontiveros-Padilla L, et al. 2021. *Microorganisms.* 9: . [PubMed](#)
28. Geiger R, et al. 2016. *Cell.* 167:829-842. [PubMed](#)
29. Fujita Y et al. 2018. *Cell reports.* 24(12):3296-3311 . [PubMed](#)
30. Sokol CL et al. 2018. *Immunity.* 49(3):449-463 . [PubMed](#)
31. Terashima Y, et al. 2020. *Nat Commun.* 11:609. [PubMed](#)
32. Hillel-Karniel C, et al. 2020. *Cell Reports.* 30(3):807-819.e4. . [PubMed](#)
33. Li H, et al. 2022. *Theranostics.* 12:6422. [PubMed](#)
34. Ji B, et al. 2016. *Cell Death Differ.* 23:759-75. [PubMed](#)
35. Atkinson S, et al. 2016. *Dis Model Mech.* 9: 427-440. [PubMed](#)
36. Hrdinka M, et al. 2016. *PLoS One.* 11: 0162863. [PubMed](#)
37. Jasti S, et al. 2017. *Biol Reprod.* 96:134. [PubMed](#)
38. Pardy RD, et al. 2021. *Nat Commun.* 12:4051. [PubMed](#)
39. Melissa M Remy et al. 2017. *Cell host & microbe.* 22(3):354-365 . [PubMed](#)
40. Kulkarni R, et al. 2021. *PLoS One.* 16:e0257191. [PubMed](#)
41. Galeano Niño JL, et al. 2020. *J Cell Sci.* 133:00:00. [PubMed](#)
42. Lim CX, et al. 2020. *Cell Rep.* 3793:30. [PubMed](#)
43. Van Braeckel-Budimir N, et al. 2018. *Cell Rep.* 24:3374. [PubMed](#)
44. Tian Y, et al. 2016. *J Immunol.* 197: 1308 - 1321. [PubMed](#)
45. Kondo M, et al. 2016. *J Immunol.* 196: 563 - 572. [PubMed](#)

46. Ren Y, *et al.* 2015. *Sci Rep.* 5: 18099. [PubMed](#)
47. Kälén S *et al.* 2017. *Cell metabolism.* 26(3):475-492 . [PubMed](#)
48. López MJ, *et al.* 2018. *Invest Ophthalmol Vis Sci.* 59:5671. [PubMed](#)
49. Frost JN, *et al.* 2021. *Med (N Y).* 2:164. [PubMed](#)
50. De Ponte Conti B, *et al.* 2021. *Elife.* 10: [PubMed](#)
51. Chun N, *et al.* 2021. *JCI Insight.* 6: [PubMed](#)
52. Daneshmandi S, *et al.* 2021. *Elife.* 10: [PubMed](#)
53. Mohebiany AN, *et al.* 2020. *Cell Reports.* 30(5):1585-1597.e6.. [PubMed](#)
54. Zhang Q, *et al.* 2021. *Front Cell Dev Biol.* 9:655552. [PubMed](#)
55. Blanchard L, *et al.* 2022. *STAR Protoc.* 3:101444. [PubMed](#)
56. Lou Y, *et al.* 2021. *Int J Mol Sci.* 22: [PubMed](#)
57. Dahlgren MW *et al.* 2019. *Immunity.* 50(3):707-722 . [PubMed](#)
58. Engblom C, *et al.* 2017. *Science.* 358:6367. [PubMed](#)
59. Waight JD, *et al.* 2018. *Cancer Cell.* 33:1033. [PubMed](#)
60. Tian Q, *et al.* 2022. *Front Mol Neurosci.* 15:850904. [PubMed](#)
61. Kwok T, *et al.* 2022. *Front Aging.* 3:838943. [PubMed](#)
62. Daneshmandi S, *et al.* 2021. *Cell Reports.* 34(10):108831. [PubMed](#)
63. Fernández-Orth J, *et al.* 2020. *Eur J Immunol.* . [PubMed](#)
64. O'Leary CE, *et al.* 2021. *Curr Protoc.* 1:e77. [PubMed](#)
65. Clemente-Casares X, *et al.* 2017. *Immunity.* 47:974. [PubMed](#)
66. Yu H, *et al.* 2021. *Cell Death Dis.* 13:1. [PubMed](#)
67. Zhang Z, *et al.* 2020. *Nature.* 579:415. [PubMed](#)
68. Wang X, *et al.* 2022. *Elife.* 11: [PubMed](#)
69. Heckler M, *et al.* 2021. *Cancer Discov.* Online ahead of prin. [PubMed](#)
70. Serr I, *et al.* 2016. *Nat Commun.* 7:10991. [PubMed](#)
71. Pflügler S, *et al.* 2020. *Commun Biol.* 3:252. [PubMed](#)
72. Akhand SS, *et al.* 2020. *Cancer Immunol Res.* 8:1542. [PubMed](#)
73. Chen D, *et al.* 2021. *JCI Insight.* 6: [PubMed](#)
74. Gawish R, *et al.* 2022. *Elife.* 11: [PubMed](#)
75. Wolf Y, *et al.* 2019. *Cell.* 179:219. [PubMed](#)
76. Quijano-Rubio A, *et al.* 2022. *Nat Biotechnol.* Online ahead of print. [PubMed](#)

**RRID** AB\_493426 (BioLegend Cat. No. 100728)  
 AB\_493425 (BioLegend Cat. No. 100725)

## Antigen Details

---

<b>Structure</b>	Ig superfamily, CD8α chain, 34 kD
<b>Distribution</b>	Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells
<b>Function</b>	Co-receptor for TCR
<b>Ligand/Receptor</b>	MHC class I molecule
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press.</li> <li>2. Zamoyska R. 1994. <i>Immunity</i> 1:243.</li> <li>3. Ellmeier W, <i>et al.</i> 1999. <i>Annu. Rev. Immunol.</i> 17:523.</li> </ol>
<b>Gene ID</b>	<a href="#">12525</a>

## Related Protocols

---

[Cell Surface Flow Cytometry Staining Protocol](#)


## Other Formats

---

APC anti-mouse CD8a, Biotin anti-mouse CD8a, FITC anti-mouse CD8a, PE anti-mouse CD8a, PE/Cyanine5 anti-mouse CD8a, Purified anti-mouse CD8a, PE/Cyanine7 anti-mouse CD8a, APC/Cyanine7 anti-mouse CD8a, Alexa Fluor® 488 anti-mouse CD8a, Alexa Fluor® 647 anti-mouse CD8a, Pacific Blue™ anti-mouse CD8a, Alexa Fluor® 700 anti-mouse CD8a, PerCP/Cyanine5.5 anti-mouse CD8a, PerCP anti-mouse CD8a, Brilliant Violet 421™ anti-mouse CD8a, Brilliant Violet 570™ anti-mouse CD8a, Brilliant Violet 650™ anti-mouse CD8a, Brilliant Violet 605™ anti-mouse CD8a, Ultra-LEAF™ Purified anti-mouse CD8a, Brilliant Violet 711™ anti-mouse CD8a, Brilliant Violet 785™ anti-mouse CD8a, Brilliant Violet 510™ anti-mouse CD8a, Purified anti-mouse CD8a (Maxpar® Ready), Alexa Fluor® 594 anti-mouse CD8a, PE/Dazzle™ 594 anti-mouse CD8a, APC/Fire™ 750 anti-mouse CD8a, GolnVivo™ Purified anti-mouse CD8a, TotalSeq™-A0002 anti-mouse CD8a, Spark Blue™ 550 anti-mouse CD8a, Spark NIR™ 685 anti-mouse CD8a, TotalSeq™-C0002 anti-mouse CD8a, TotalSeq™-B0002 anti-mouse CD8a, Spark YG™ 570 anti-mouse CD8a, PE/Fire™ 640 anti-mouse CD8a, PE/Fire™ 700 anti-mouse CD8a, Spark Blue™ 574 anti-mouse CD8a Antibody, Spark Violet™ 423 anti-mouse CD8a Antibody, Spark UV™ 387 anti-mouse CD8a

## Product Data

---



C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) Pacific Blue™ (filled histogram) or rat IgG2a, κ Pacific Blue™ isotype control (open histogram).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587